The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma
-
Published:2024-07
Issue:
Volume:595
Page:216997
-
ISSN:0304-3835
-
Container-title:Cancer Letters
-
language:en
-
Short-container-title:Cancer Letters
Author:
Ito YoshiroORCID,
Yamada Daisaku,
Kobayashi ShogoORCID,
Sasaki Kazuki,
Iwagami YoshifumiORCID,
Tomimaru Yoshito,
Asaoka Tadafumi,
Noda Takehiro,
Takahashi Hidenori,
Shimizu Junzo,
Doki Yuichiro,
Eguchi HidetoshiORCID
Reference31 articles.
1. Current and emerging therapies for advanced biliary tract cancers;Kam;Lancet Gastroenterol Hepatol,2021
2. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study;Primrose;Lancet Oncol.,2019
3. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention;Lowery;Clin. Cancer Res.,2018
4. Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements;Walden;Therap Adv Gastroenterol,2022
5. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study;Javle;Lancet Gastroenterol Hepatol,2021